Cargando…

Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies

BACKGROUND: To evaluate the psychometric and measurement properties of two patient-reported outcome instruments, the menstrual pictogram superabsorbent polymer-containing version 3 (MP SAP-c v3) and Uterine Fibroid Daily Bleeding Diary (UF-DBD). Test-retest reliability, criterion, construct validity...

Descripción completa

Detalles Bibliográficos
Autores principales: Haberland, Claudia, Filonenko, Anna, Seitz, Christian, Börner, Matthias, Gerlinger, Christoph, Doll, Helen, Wessiepe, Dorothea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666240/
https://www.ncbi.nlm.nih.gov/pubmed/33185783
http://dx.doi.org/10.1186/s41687-020-00263-0
_version_ 1783610096953065472
author Haberland, Claudia
Filonenko, Anna
Seitz, Christian
Börner, Matthias
Gerlinger, Christoph
Doll, Helen
Wessiepe, Dorothea
author_facet Haberland, Claudia
Filonenko, Anna
Seitz, Christian
Börner, Matthias
Gerlinger, Christoph
Doll, Helen
Wessiepe, Dorothea
author_sort Haberland, Claudia
collection PubMed
description BACKGROUND: To evaluate the psychometric and measurement properties of two patient-reported outcome instruments, the menstrual pictogram superabsorbent polymer-containing version 3 (MP SAP-c v3) and Uterine Fibroid Daily Bleeding Diary (UF-DBD). Test-retest reliability, criterion, construct validity, responsiveness, missingness and comparability of the MP SAP-c v3 and UF-DBD versus the alkaline hematin (AH) method and a patient global impression of severity (PGI-S) were analyzed in post hoc trial analyses. RESULTS: Analyses were based on data from up to 756 patients. The full range of MP SAP-c v3 and UF-DBD response options were used, with score distributions reflecting the cyclic character of the disease. Test-retest reliability of MP SAP-c v3 and UF-DBD scores was supported by acceptable intraclass correlation coefficients when stability was defined by the AH method and Patient Global Impression of Severity (PGI-S) scores (0.80–0.96 and 0.42–0.94, respectively). MP SAP-c v3 and UF-DBD scores demonstrated strong and moderate-to-strong correlations with menstrual blood loss assessed by the AH method. Scores increased in monotonic fashion, with greater disease severities, defined by the AH method and PGI-S scores; differences between groups were mostly statistically significant (P < 0.05). MP SAP-c v3 and UF-DBD were sensitive to changes in disease severity, defined by the AH method and PGI-S. MP SAP-c v3 and UF-DBD showed a lower frequency of missing patient data versus the AH method, and good agreement with the AH method. CONCLUSIONS: This evidence supports the use of the MP SAP-c v3 and UF-DBD to assess clinical efficacy endpoints in UF phase III studies replacing the AH method.
format Online
Article
Text
id pubmed-7666240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-76662402020-11-16 Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies Haberland, Claudia Filonenko, Anna Seitz, Christian Börner, Matthias Gerlinger, Christoph Doll, Helen Wessiepe, Dorothea J Patient Rep Outcomes Research BACKGROUND: To evaluate the psychometric and measurement properties of two patient-reported outcome instruments, the menstrual pictogram superabsorbent polymer-containing version 3 (MP SAP-c v3) and Uterine Fibroid Daily Bleeding Diary (UF-DBD). Test-retest reliability, criterion, construct validity, responsiveness, missingness and comparability of the MP SAP-c v3 and UF-DBD versus the alkaline hematin (AH) method and a patient global impression of severity (PGI-S) were analyzed in post hoc trial analyses. RESULTS: Analyses were based on data from up to 756 patients. The full range of MP SAP-c v3 and UF-DBD response options were used, with score distributions reflecting the cyclic character of the disease. Test-retest reliability of MP SAP-c v3 and UF-DBD scores was supported by acceptable intraclass correlation coefficients when stability was defined by the AH method and Patient Global Impression of Severity (PGI-S) scores (0.80–0.96 and 0.42–0.94, respectively). MP SAP-c v3 and UF-DBD scores demonstrated strong and moderate-to-strong correlations with menstrual blood loss assessed by the AH method. Scores increased in monotonic fashion, with greater disease severities, defined by the AH method and PGI-S scores; differences between groups were mostly statistically significant (P < 0.05). MP SAP-c v3 and UF-DBD were sensitive to changes in disease severity, defined by the AH method and PGI-S. MP SAP-c v3 and UF-DBD showed a lower frequency of missing patient data versus the AH method, and good agreement with the AH method. CONCLUSIONS: This evidence supports the use of the MP SAP-c v3 and UF-DBD to assess clinical efficacy endpoints in UF phase III studies replacing the AH method. Springer International Publishing 2020-11-13 /pmc/articles/PMC7666240/ /pubmed/33185783 http://dx.doi.org/10.1186/s41687-020-00263-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Haberland, Claudia
Filonenko, Anna
Seitz, Christian
Börner, Matthias
Gerlinger, Christoph
Doll, Helen
Wessiepe, Dorothea
Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title_full Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title_fullStr Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title_full_unstemmed Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title_short Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
title_sort validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666240/
https://www.ncbi.nlm.nih.gov/pubmed/33185783
http://dx.doi.org/10.1186/s41687-020-00263-0
work_keys_str_mv AT haberlandclaudia validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT filonenkoanna validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT seitzchristian validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT bornermatthias validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT gerlingerchristoph validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT dollhelen validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies
AT wessiepedorothea validationofamenstrualpictogramandadailybleedingdiaryforassessmentofuterinefibroidtreatmentefficacyinclinicalstudies